Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy

Neuropediatrics

Volumn 29, Issue 4, 1998, Pages 195-201

  Graf, W D ^a,b,f   Oleinik, O E ^a   Glauser, T A ^c   Maertens, P ^d   Eder, D N ^b   Pippenger, C E ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^e FRESA BioMedical Laboratories   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Antioxidants; Glutathione; Glutathione peroxidase; Selenium; Valproic acid

Indexed keywords

ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CATALASE; COPPER; ERYTHROCYTE ENZYME; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; SELENIUM; SUPEROXIDE DISMUTASE; TRACE ELEMENT; VALPROIC ACID; ZINC;

ADOLESCENT; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER; BLOOD LEVEL; CONTROLLED STUDY; DEATH; DRUG DETOXIFICATION; DRUG OXIDATION; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA; VOMITING;

EID: 0031829096     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-973560     Document Type: Article

References (53)

1. Appleton, R. E., Farrell, K., Applegarth, D. A. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 17, 145-148 (1990).
2. Baillie, T. A. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol 1, 195-199 (1988).
3. Baillie, T., Levy, R. Metabolic fate of valproic acid in humans. In: Levy, R., Penry, J. (Eds.): Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity. New York, Raven Press, Ltd. 19-24 (1991).
4. Becker, C. M., Harris, R. A. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch. Biochem. Biophys. 223, 381-392 (1983).
5. Bettger, W. J. Zinc and selenium, site-specific versus general antioxidation. Can. J. Physiol. Pharmacol. 71, 721-724 (1993).
6. Bryant, A. E., III, Dreifuss, F. E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46, 465-469 (1996).
7. Burk, R. F., Hill, K. E., Awad, J. A., Morrow, J. D., Kato, T., Cockell, K. A., et al. Pathogenesis of diquat-induced liver necrosis in selenium-deficient rats: assessment of the roles of lipid peroxidation and selenoprotein P. Hepatology 21, 561-569 (1995).
8. Burk, R. F., Hill, K. E. Regulation of selenoproteins. Annu. Rev. Nutr. 13, 65-81 (1993).
9. Camfield, P. R., Bagnell, P., Camfield, C. S., Tibbles, J. A. R. Pancreatitis due to valproic acid. Lancet 2, 1198-1199 (1979).
10. Carlberg, I., Mennervik, B. Glutathione reductase. Methods Enzymol. 113, 484-490 (1985).
11. Chambers, I., Frampton, J., Goldfarb, P., Affaran, N., McBain, W., Harrison, P. The structure of the mouse glutathione peroxidase gene: the selenocysteine in the active site is encoded by the "termination" codon, TGA. EMBO J. 5, 1221-1227 (1986).
12. Christensen, M. J., Nelson, B. L., Wray, C. D. Regulation of gluathione S-transferase gene expression and activity by dietary selenium. Biochem. Biophys. Res. Commun. 202, 271-277 (1994).
13. Cohen, H. J., Brown, M. R., Hamilton, D., Lyons-Patterson, J., Avissar, N., Liegey, P. Glutathione peroxidase and selenium deficiency in patients receiving home parenteral nutrition: time course for development of deficiency and repletion of enzyme activity in plasma and blood cells. Am. J. Clin. Nutr. 49, 132-139 (1989).
14. Cooper, A. J. L. Glutathione in the brain: disorders of glutathione metabolism. In: Rosenberg, R. N., Prusiner, S. B., DiMauro, S., Barchi, R. L. (Eds.). The Molecular and Genetic Basis of Neurological Disease. Boston, Butterworth-Heinemann 1195-1230 (1997).
15. Cotariu, D., Evans, S., Zaidman, J. L., Marcus, O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem. Pharmacol. 40, 589-593 (1990).
16. Delgado, M. R., Riela, A. R., Mills, J., Browne, R., Roach, E. S. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J. Child Neurol. 9, 311-314 (1994).
17. Dickinson, R., Hooper, W., Eddie, M. pH dependent rearangement of the biosynthetic ester glucoronide of valproic acid to beta-glucuronidase-resistant forms. Drug Metab. Dispos. 12, 247-252 (1984).
18. Dreifuss, F. E., Santilli, N., Langer, D. H., Sweeny, K. P., Moline, B. A., Menander, K. B. Valproic acid fatalities: a retrospective review. Neurology 37, 379-385 (1987).
19. Eadie, M., Hooper, W., Dickinson, R. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. 3, 85-106 (1988).
20. Farrell, K., Abbott, F. S. Role of N-acetylcysteine in the treatment of valproate hepatotoxicity. In: Levy, R, H., Penry, J. K. (Eds.). Idiosyncratic Reations to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity. New York, Raven Press, Ltd. 149-153 (1991).
21. Fisher, E., Siemes, H., Pund, R., Wittfoht, W., Nau, H. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 33, 165-171 (1992).
22. Gerber, N., Dickinson, R. G., Harland, R. C., Lynn, R. K., Houghton, D., Antonias, J. I., et al. Reye like syndrome associated with valproic acid therapy. J. Pediatr. 95, 142-144 (1979).
23. Granneman, G. R., Wang, S.-I., Kesterson, J. W., Machinist, J. M. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 4, 1153-1158 (1984).
24. Holtzman, J. Role of reactive oxygen and metabolite binding in drug toxicity. Life Sci. 30, 1-9 (1982).
25. Hurd, R.W., Van Rinsvelt, H. A., Wilder, B. J., Karas, B., Maehaut, W., De Leu, L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 34, 1393-1395 (1984).
26. Jacob, R. A. Trace elements. In: Tietz, N. W. (Eds.). Textbook of Clinical Chemistry. Philadelphia, W. B. Saunders 965-996 (1986).
27. Johansson, L. H., Håkan Borg, L. A. Spectrophotometric method for determination of catalase activity in small tissue samples. Anal. Biochem. 174, 331-336 (1988).
28. Keller, B. J., Yamanaka, G., Thurman, R. G. Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology 71, 49-61 (1992).
29. Kerr, B. M., Rettie, A. E., Eddy, A. C., Loiseau, P., Guyot, M., Wilensky, A. J., et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin. Pharmacol. Ther. 46, 82-93 (1989).
30. Kesterson, J. W., Granneman, G. R., Machinist, J. M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4, 1143-1152 (1984).
31. Kochen, W., Schneider, A., Ritz, A. Abnormal metabolism of VPA in fatal hepatic failure. Eur. J. Pediatr. 141, 30-35 (1983).
32. Kondo, T., Kaneko, S., Otani, K., Ishida, M., Hirano, T., Fukushima, Y., et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 33, 172-177 (1992).
33. Konig, S. A., Siemes, H., Blaker, F., Boenigk, E., Gross-Selbeck, G., Hanefeld, F., et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35, 1005-1015 (1994).
34. Kuhara, T., Inoue, Y., Matsumoto, M., Shinka, T., Matsumoto, I., Kawahara, N., et al. Markedly increased w-oxidation of valproate in fulminant hepatic failure. Epilepsia 31, 214-217 (1990).
35. Lei, X., Everson, J., Thompson, K., Sunde, R. Glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase are differentially regulated in rats by dietary selenium. J. Nutr. 125, 1438-1446 (1995).
36. Levy, R. H., Rettenmeier, A. W., Anderson, G. D., Wilensky, A. J., Friel, P. N., Baillie, T. A., et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-en-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 48, 225-235 (1990).
37. Lombeck, I., Kasperek, K., Bachmann, D., Feinendegen, L., Bremer, H. Selenium requirements in patients with inborn errors of amino acid metabolism and selenium deficiency. Eur. J. Pediatr. 134, 65-68 (1980).
38. McCord, J. M., Fridovich, I. Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049-6055 (1969).
39. Meister, A. Glutathione metabolism and its selective modification. J. Biol. Chem. 263, 17205-17208 (1988).
40. Mitchell, J., Jollow, D., Potter, W., Gillette, J., Brodie, B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther. 187, 211-217 (1973).
41. Nelson, S. Metabolic activation and drug toxicity. J. Med. Chem. 25, 753-765 (1982).
42. Nohl, H., Jordan, W. The mitochondrial site of superoxide formation. Biochem. Biophys. Res. Comm. 198, 533-539 (1986).
43. Paglia, D. E., Valentine, W. N. Studies of the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70, 158-169 (1967).
44. Rettenmeier, A. W., Gordon, W. P., Prickett, K. S., Levy, R. H., Lockard, J. S., Thummel, K. E., et al. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab. Dispos. 14, 443-453 (1986).
45. Rettie, A. E., Rettenmeier, A. W., Howald, W. N., Baillie, T. A. Cytochrome P-450-catalyzed formation of delta-4-VPA, a toxic metabolite of valproic acid. Science 235, 890-893 (1987).
46. Scheffner, D., König, S., Rauterberg-Ruland, I., Kochen, W., Hofmann, W. J., Unkelbach, S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 29, 530-542 (1988).
47. SPSS: SPSS for Windows. Chicago (1989-1994).
48. Tennison, M. B., Miles, M. V., Pollack, G. M., Thorn, M. D., Dupuis, R. E. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 29, 543-547 (1988).
49. Thurston, J. H., Carroll, J. E., Hauhart, R. E., Shiro, J. A. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance. Life Sci. 36, 1643-1651 (1985).
50. Warholm, M., Guthenberg, C., von Bahr, C., Mannerik, B. Glutathione transferases from human liver. Methods. Enzymol. 113, 499-504 (1985).
51. Willmore, L. J. Clinical manifestations of valproate hepatotoxicity. In: Levy, R. H., Penry, J. K. (Eds.). Idiosyncratic Reactions to Valproate. New York, Raven 47-52 (1991).
52. Xia, Y., Hill, K. E., Burk, R. F. Biochemical studies of a selenium deficient population in China: measurement of selenium, glutathione peroxidase and other oxidant defense indices in blood. J. Nutr. 119, 1318-1326 (1989).
53. Zimmerman, H. J., Ishak, K. G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2, 591-597 (1982).